choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Mircera

Mircera Newsletter
  • Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024) 24 Apr 2024 08:09 GMT

    … , a subcutaneous combination drug containing Perjeta. Specialty … In addition, sales of Mircera (a long-acting erythropoiesis … China by the National Medical Products Administration (NMPA) … the treatment of endometriosis in January 2024. Chugai Pharmaceutical Co …

  • Erythropoietin Drugs Market valued at US$13.803 billion in 2022, to witness significant growth 20 Feb 2024 14:23 GMT

    … developed through biotechnological processes and … pharmaceutical products and medical treatments. The market analytics report segments the erythropoietin drugs … Pharmaceuticals Ltd. • FosunPharma • Rewine Pharmaceuticals • Kyowa Kirin • Mircera …

  • Genexine seeks approval for anemia treatment in Korea 26 Jan 2024 10:38 GMT

    Korean biotech firm Genexine announced Friday … Efesa is intended for the treatment and maintenance of anemia induced … Genexine started phase 3 clinical trials for patients with non-dialysis … 39;s third-generation anemia drug Mircera maintained a response rate of …

  • Genexine completes BLA submission for anemia treatment 26 Jan 2024 07:24 GMT

    … Drug Safety (MFDS) for Efesa (efepoetin alfa), its anemia treatment … Drug Authority (BPOM) after the successful completion of phase 3 clinical trials … Mircera. “Based on the phase 3 clinical trial results … domestic biotech company to complete the entire drug …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 12-Month High at $19.68 12 Jan 2024 15:19 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an … analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 1-Year High at $19.61 29 Dec 2023 17:03 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an … analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Declines By 81.1% 14 Dec 2023 18:42 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an … analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 1-Year High at $17.67 02 Dec 2023 13:17 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an … analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 52-Week High at $16.34 18 Nov 2023 15:22 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an … analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Posts Quarterly Earnings Results 27 Oct 2023 15:35 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an … analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

Satisfied with the content?

Continue to create your account.